Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy

Clinica Chimica Acta

Volumn 411, Issue 9-10, 2010, Pages 762-764

  Yamamoto, Daisuke ^a   Takai, Shinji ^a   Hirahara, Ichiro ^b   Kusano, Eiji ^b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Continuous ambulatory peritoneal dialysis; Matrix metalloproteinase 2

Indexed keywords

CAPTOPRIL; GELATINASE A;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; IC 50; KIDNEY FAILURE; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; SIMULATION;

ASCITIC FLUID; BIOCATALYSIS; CAPTOPRIL; CATALYTIC DOMAIN; FEMALE; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MOLECULAR DYNAMICS SIMULATION; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEAL FIBROSIS; PROTEIN BINDING;

EID: 77950459472     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.02.059     Document Type: Article

References (23)

1. Gandhi V.C., Humayun H.M., Ing T.S., et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980, 140:1201-1203.
2. Slingeneyer A., Mion C., Mourad G., Canaud B., Faller B., Beraud J.J. Progressive sclerosing peritonitis: a late and severe complication of maintenance peritoneal dialysis. Trans Am Soc Artif Intern Organs 1983, 29:633-640.
3. Dobbie J.W. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992, 12:14-27.
4. Kawaguchi Y., Kawanishi H., Mujais S., Topley N., Oreopoulos D.G. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000, 20(Suppl 4):S43-S55.
5. Hirahara I., Inoue M., Okuda K., Ando Y., Muto S., Kusano E. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis - a multicentre study in Japan. Nephrol Dial Transplant 2007, 22:560-567.
6. Hirahara I., Umeyama K., Urakami K.-I., Kusano E., Masunaga Y., Asano Y. Serial analysis of matrix metalloproteinase-2 in dialysate of rat sclerosing peritonitis models. Clin Exp Nephrol 2001, 5:103-108.
7. Hirahara I., Kusano E., Yanagiba S., et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int 2006, 26:380-392.
8. Hirahara I., Ishibashi Y., Kaname S., Kusano E., Fujita T. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant 2009, 24:437-447.
9. Mann J.F., Gerstein H.C., Pogue J., Bosch J., Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-636.
10. Hou F.F., Zhang X., Zhang G.H., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006, 354:131-140.
11. Efrati S., Zaidenstein R., Dishy V., et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002, 40:1023-1029.
12. Fang W., Oreopoulos D.G., Bargman J.M. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 2008, 23:3704-3710.
13. Sorbi D., Fadly M., Hicks R., Alexander S., Arbeit L. Captopril inhibits the 72kDa and 92kDa matrix metalloproteinases. Kidney Int 1993, 44:1266-1272.
14. Dhanaraj V., Williams M.G., Ye Q.Z., et al. X-ray structure of gelatinase A catalytic domain complexed with a hydroxamate inhibitor. Croatica Chem Acta 1999, 72:575-591.
15. Natesh R., Schwager S.L., Evans H.R., Sturrock E.D., Acharya K.R. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry 2004, 43:8718-8724.
16. Kim H.M., Shin D.R., Yoo O.J., Lee H., Lee J.O. Crystal structure of drosophila angiotensin I-converting enzyme bound to captopril and lisinopril. FEBS Lett 2003, 538:65-70.
17. Yamamoto D., Takai S., Miyazaki M. Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol 2008, 588:277-279.
18. Yamamoto D., Takai S., Miyazaki M. Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochem Biophys Res Commun 2007, 354:981-984.
19. Yamamoto D., Takai S., Jin D., Inagaki S., Tanaka K., Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol 2007, 43:670-676.
20. Yamamoto D., Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Curr Med Chem 2009, 16:1349-1354.
21. Ro Y., Hamada C., Inaba M., Io H., Kaneko K., Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007, 22:2838-2848.
22. Kolesnyk I., Noordzij M., Dekker F.W., Boeschoten E.W., Krediet R.T. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 2009, 24:272-277.
23. 2-dependent matrix metalloproteinase activity. Circulation 2004, 109:1482-1488.